Immuneering Q2 net loss $7.9M; IPO raised $129.4M; IMM-1-104 IND expected Q1 2022

Immuneering Corp

Net loss of $7.9M ($1.61/share) vs $3.6M ($0.73/share) in Q2 2020.
Cash $50.2M at June 30, 2021; excludes $118.3M net IPO proceeds from August 2021.
R&D expenses $7.0M, up from $3.2M YoY on preclinical costs and personnel.
Completed upsized IPO of 8.625M shares at $15.00/share for $129.4M gross.
IND filing for IMM-1-104 (RAF-MEK inhibitor) planned for Q1 2022; Phase 1 start H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.